Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of SAR443820 (Oditrasertib) in Healthy Volunteers
NCT05797701Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oditrasertib in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Jul 2021; status: completed.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05797701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797701.